ArticleHealthcare policy = Politiques de sante2007
Influencing Drug Prices through Formulary-Based Policies: Lessons from New Zealand.
Article in Healthcare policy = Politiques de sante, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 55 citations in OpenAlex.
- Validating the rigour of adaptive methods of economic evaluation.BMJ global health · 2023Article
- Leading Causes of Mortality and Prescription Drug Coverage in Canada and New Zealand.Frontiers in public health · 2020Article
- Ontario and New Zealand Pharmaceuticals: Cost and Coverage.Healthcare policy = Politiques de sante · 2018Article
- Is Canadian Healthcare Affordable? A Comparative Analysis of the Canadian Healthcare System from 2004 to 2014.Healthcare policy = Politiques de sante · 2017Article
- Drivers of expenditure on primary care prescription drugs in 10 high-income countries with universal health coverage.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2017Article
- Estimated effects of adding universal public coverage of an essential medicines list to existing public drug plans in Canada.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2017Article
- Universal prescription drug coverage in Canada: Long-promised yet undelivered.Healthcare management forum · 2016Review
- A Better Prescription: Advice for a National Strategy on Pharmaceutical Policy in Canada.Healthcare policy = Politiques de sante · 2016Article
- National pharmacare: Time to move forward.Canadian family physician Medecin de famille canadien · 2016Article
- [Assurance-médicaments nationale: Le moment d'aller de l'avant].Canadian family physician Medecin de famille canadien · 2016Article
- Disinvestment and Value-Based Purchasing Strategies for Pharmaceuticals: An International Review.PharmacoEconomics · 2015Review
- Estimated cost of universal public coverage of prescription drugs in Canada.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2015Article
- The increasing inefficiency of private health insurance in Canada.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2014Article
- Pan-Canadian overpricing of medicines: a 6-country study of cost control for generic medicines.Open medicine : a peer-reviewed, independent, open-access journal · 2014Article
- The road to competitive generic drug prices in Canada.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2013Article
- Money left on the table: generic drug prices in Canada.Healthcare policy = Politiques de sante · 2013Article
- A qualitative evaluation of general practitioners' perceptions regarding access to medicines in New Zealand.BMJ open · 2012Article
- Purchasing prescription drugs in Canada: hang together or hang separately.Healthcare policy = Politiques de sante · 2011Article
- The short-term impact of Ontario's generic pricing reforms.PloS one · 2011Article
- Breadth, Depth and Agreement among Provincial Formularies in Canada.Healthcare policy = Politiques de sante · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A national formulary has been proposed as a priority element of Canada's National Pharmaceuticals Strategy. We review a variety of formulary-based policies that might be used in conjunction with a national formulary, drawing on the policies and practices of the Pharmaceutical Management Agency of New Zealand. We consider the potential price impact of an actively managed national formulary by conducting a Canada-New Zealand price comparison for equivalent products in the four largest drug classes: statins, angiotensin-coverting enzyme (ACE) inhibitors, selective serotonin reuptake inhibitors (SSRIs) and proton pump inhibitors (PPIs). The results suggest that potential price savings for Canada in these drug classes are on the order of 21% to 79%. Such price differences would translate into billions of dollars in annual savings if applied across Canada, potentially offsetting the costs of the expansion of pharmacare coverage necessary to achieve both equity and efficiency goals in this sector.
Identifiers
19305747PMC2645129W2091931875What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.